New York was hit hard by the COVID-19 pandemic due to high population density and the public transport system, but what happened to people with multiple sclerosis who got COVID-19 in New York? This study from New York University seeks to answer that question. We look at overall mortality and hospitalization rates and different disease modifying therapies such as Ocrevus, Gilenya, and Tysabri.

Here is the article I am discussing: https://nn.neurology.org/content/7/5/…